Imprimir esta página
Martes, 02 Enero 2007 23:32

Askbio recibe $2,5m para la investigación

[original url="http://triangle.bizjournals.com/triangle/stories/2006/12/11/daily18.html?jst=b_ln_hl"]Bizjournals.com[/original]

La asociación de distrofia muscular de EEUU acaba de dar fondos de $2,5 millones de dólares a Askbio para pagar para ensayos de un posible tratamiento para Duchenne. La empresa, Asklepios BioPharmaceutical Inc., dice que ellos pondrán fondos equivalentes para soportar el estudio de Biostrophin, su posible tratamiento de Duchenne.

La empresa esta actualmente probando la seguridad de este nuevo medicamento, administrándole a un solo músculo de seis personas con distrofia.

En un anuncio escrito recientemente la empresa ha dicho que los nuevos fondos permitirán a Asklepios pagar para la siguiente etapa de los ensayos, que probaran la seguridad y eficacia de Biostrophin en perros y monos.

"El siguiente etapa en este proyecto es importante para verificar que podemos administrar Biostrophin a múltiples músculos a la vez," dice Sharon Hesterlee, vice presidente de Translational Research del MDA

AskBio es una empresa privada, sin ánimo de lucro, especializada en la fase de desarrollo de biotecnología. Ha sido creado por la Universidad del Norte de Carolina, EEUU. En este momento tiene aprox. cinco empleados.

[Copia del articulo original]

 

The Muscular Dystrophy Association has granted $2.5 million to a Chapel Hill biopharmaceutical firm to pay for continued trials of a gene therapy targeting Duchenne muscular dystrophy.

Asklepios BioPharmaceutical Inc. said it will match the MDA grant to fund continued trials of Biostrophin, its lead gene therapy for DMD. 


The company currently is testing the safety of administering Biostrophin into a single muscle of six human patients with the disease.

The new funds will enable Asklepios to pay for the next stage of trials, which will test the safety and effectiveness of Biostrophin in canine and non-human primate models, according to a written statement released by the company Tuesday.

"The next step in this project is important to establish that we can deliver (Biostrophin) to multiple muscles at once," Sharon Hesterlee, vice president of Translational Research at MDA, said in a written statement.

The $2.5 million grant is the largest grant MDA has awarded to a for-profit company. MDA provided $1.6 million for the first phase of the trial.

There currently is no life-sustaining treatment for the disease, which is genetically inherited.

AskBio is a private development-stage biotechnology company that was spun out from the University of North Carolina at Chapel Hill. It currently has about five full-time employees.

Leer 3513 veces Modificado por última vez en Martes, 10 Enero 2012 13:40